ClinicalTrials.gg
Active, not recruitingNCT05933330DAN-HEMTEL-VMUpdated Mar 30, 2025

Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database

An observational study in Telangiectasia, Hereditary Hemorrhagic and Intracranial Arteriovenous Malformations, sponsored by Odense University Hospital. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Odense University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 65 Years
Sex
All
01

Study summary

With a described prevalence of brain arteriovenous malformations (CAVM) of 12.8% in HHT patients, of whom 10% presents with intracranial hemorrhage, HHT pose a risk of devastating intracranial hemorrhage.

The main objective of the study is to challenge current statements (pros and cons) regarding systematic screening of asymptomatic HHT patients for neurovascular manifestations.

The investigators are thus seeking to answer a question many screening programs have faced.

A screening program should screen for a manageable problem, by a method that is considered cost effective and does not cause negative effect, even when extrapolated to a large cohort. Finally, the positive effect of screening program should outweigh the negative and not cause unnecessary concerns for the patients. The investigators are seeking to draw perspectives from the results to general questions about screening programs.

Read the detailed description

The Investigators are conducting a study investigating the disease, Hereditary Hemorrhagic Telangiectasia (HHT) and its neuro-logical and -vascular manifestations.

With a described prevalence of brain arteriovenous malformations (CAVM) of 12.8% in HHT patients, of whom 10% presents with intracranial hemorrhage, HHT pose a risk of devastating intracranial hemorrhage.

The main objective of the study is to challenge current statements (pros and cons) regarding systematic screening of asymptomatic HHT patients for neurovascular manifestations.

The investigators seek to fulfill the objective by offering all Danish HHT patients between 18-65 years of age, an MRI of the brain. Participants are asked to answer two questionnaires (SF-36 and BDI II) before and after the MRI. 100 participants are offered an MRI ASL in order, to investigate if this MRI sequence is more suitable to seek out vascular malformations of the brain.

The study is being performed at the University Hospital of Odense; participants receive their MRI at the radiological center closest to their home address. All participants are included, informed, and briefly interviewed over the telephone. Participants will be recruited using the Danish HHT database.

The project consist of 4 main parts.

  1. Neurological manifestations of HHT.
  2. A screening of all patients in the Danish HHT database, between 18-65 years of age for CAVM.
  3. A study of the adverse psychological effect from screening HHT patients in Denmark.
  4. An investigation of the optimal screening method for CAVM.

    Part 1

    • Data included in part study 1 is collected retrospectively from the prospectively maintained Danish HHT database.

    Neurological outcomes of all patients in the database, is cross-referenced with the Danish Apoplexy Register (DAP-database), to ensure optimal quality of registered neurological outcomes.

    Part 2

    • Data included in part study 2 is MRI of brain and surgical outcome. The proposed screening method will be conventional MRI, T1, T2 and TOF, of the cerebrum of all HHT patients between 18-65 years of age (n=350). 100 patients will be investigated further with MRI arterial spin labeling (ASL) and included in part 4.

    Part 3 • Data included in part study 3 is SF-36 and BDI II questionaires baseline and 3 months after patients have received an MRI of the brain.

    Part 4 • Data included in part study 4 is MRI of the brain, with comparative ASL sequencing.

    Separated in MRI with conventional sequences compared to MRI with ASL. Data will be reported according to: Reporting standards for angiographic evaluation and endovascular treatment of cerebral arteriovenous malformations, Jayaraman et al. (2011).

    A cost-effectiveness analysis, investigating to prize of an MRI, the cost of additional follow-up of vascular malformations and incidentalomas will be summarized in this part study.

    The data comes from Danish patients with HHT, 18-65 years of age. Continues data is expected to have normal distribution, and will be tested by the shapiro-wilk test.

    In case of normal distribution, oneway anova will be used to test significant levels of difference between the 5 groups (HHT1, HHT2, JP-HHT, Unknown HHT status and not genetically verified).

    If data is not normally distributed Kruskal-Wallis test will be used to test significance.

    Multivariate analyses will be done by logistic regression and in case of non-binary ordered data, ordered logistic regression adjusting for age and gender will be used.

    Dichotomous categorical data will be analyzed of their degree of independence with chi2 test.

    As HHT is inherited autosomal dominantly, and The sample group is only selected by age (18-65 years of age), The investigators expect data to have normal distribution. In case of lack of normal distribution, this could be explained by the fact that HHT is a rare disease with varying penetrance.

    A power analyses for the project shows:

    For the BDI II and SF-36 outcomes with 289 patients a mean change from pre-screening to post-screening could be detected with 80% power if:

    • Pre-post-correlation = 0.5 (assumed to be the lowest realistic value): Change of 0,17 SD could be detected
    • Pre-post-correlation = 0.8 (assumed to be the highest realistic value): Change of 0,10 SD could be detected As a clinical relevant difference typically would be assumed to be at least 0,3 SD, any clinical relevant changes should be detectable with 289 patients.

    A preliminary investigation indicates a 95% inclusion rate (5% of patients does not want to participate, or has already recieved an MRI of brain prior to the study). The investigators expect patients to be less likely to answer the questionnaire send to them 3 months after they have received the results from their brain MRI. Every Friday after initial invitation to the follow-up questionnaire, a reminder will be sent to the patients. after 3 reminders, the patients will finally be called.

    Part 4 - optimal MRI ASL (arterial spin labeling). In order for this study to be successful, The study need at least 10 patients whom have received a brain MRI with ASL that found a Cerebral AVM. In case of lacking case patients, HHT patients who have received an ordinary MRI with angio-sequences, that showed a cerebral AVM will be invited to have an brain MRI with ASL. This examination is done to uncover whether the participants have more cerebral AVM, that is not visible on conventional MRI. previous studies has shown, that roughly, 50% of HHT patients with cerebral AVM has multiple AVMs.

    The Danish HHT center has been situated at Odense University Hospital since 1996 and all HHT patients seen at the center have been included in the national research ´database. In 2015 data were uploaded in a Red Cap database and since then all patients included in the database have received written information and given informed consent. Data regarding date of birth, age, age of diagnosis, HHT type, results of screening for PAVM, CAVM and hepatic AVM (HAVM) are included. Furthermore, data regarding age of debut of epistaxis, results regarding date of neurological events, cerebral ischemia, bleeding, and abscess are also included in the Danish HHT database.

    The study and its part studies, contains personal patient data, and is therefore under the GDPR act.

    The project is approved by the Danish Data Protection Agency and the Region of Southern Denmark´s regional secretariat of Law.

    Data from this project is owned by the Danish HHT-center, and is located at the department of ear, nose and throat surgery at OUH.

    ALL data is only published in anonymized form. Data is only exported from RedCap in pseudononymized form for the purpose of statistical analyses.

02

Conditions studied

  • Telangiectasia, Hereditary Hemorrhagic
  • Intracranial Arteriovenous Malformations
03

In context

Telangiectasia, Hereditary Hemorrhagic

106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.

This study's planned enrollment of 300 is above the median of 207 across 41 observational studies indexed under Telangiectasia, Hereditary Hemorrhagic.

Browse Telangiectasia, Hereditary Hemorrhagic studies →

Lead sponsor

Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with HHT (according to the curacao criteria or genetically verified mutations)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HHT according to the clinical diagnostic criteria (curacao)
  • 18-65 years of age.
  • registered in the Danish HHT-database

Exclusion criteria

Exclusion Criteria:

  • patients has received an MRI of the brain with angio sequences, within the last 5 years.
  • to MRI
  • contraindications to self-reported questionnaires (i.e. mental retardation)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Danish HHT patient 18-65 years of age

    Other: Brain MRI

Interventions

  • OtherBrain MRI

    All included patients receive an MRI of the brain

06

What researchers measure

Primary outcomes

  1. Number of new patients with Cerebral Arteriovenous malformation

    MRI verified arteriovenous malformation

    Time frame: 1st of April 2022 - 30th of June 2025.

Secondary outcomes

  1. Number of new patients with Ischemic stroke

    Symptomatic or silent (MRI verified) Ischemic cerebral stroke

    Time frame: 1st of April 2022 - 30th of June 2025.

  2. Number of new patients with Hemorrhagic stroke

    spontaneous CAVM rupture.

    Time frame: 1st of April 2022 - 30th of June 2025.

  3. Short Form 26

    Results from questionnaire SF-36. 0-100. 100 being the best possible.

    Time frame: Baseline - inclusion, and 3 months after screening with MRI, and (in case of treatment) 3 months after treatment. 1st of April 2022 - 30th of June 2025.

  4. MRI arterial spin labeling (ASL)

    comparison between conventional MRI angio sequences compared to MRI with ASL, in it´s ability to detect CAVM.

    Time frame: 1st of April 2022 - 30th of June 2025.

  5. Becks Depression Inventory II

    Results from questionnaire BDI II. 0-61. 61 being the most depressed possible, and 0 the "best".

    Time frame: Baseline - inclusion, and 3 months after screening with MRI, and (in case of treatment) 3 months after treatment. 1st of April 2022 - 30th of June 2025.

07

Study locations

1 site
  • Danish HHT-center. Odense University Hospital
    Odense, Fyn 5000, Denmark
08

References and documents

Individual participant data

Plan to share: Undecided — All data from the study, will be stored according to danish legislation and GDPR, in certified GDPR servers at OUH, after study completion.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Mar 2025, 35 months after the start.

Of 23 observational studies under Telangiectasia, Hereditary Hemorrhagic, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 184. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2023
First posted
Jul 6, 2023
StartActual
Apr 1, 2022
Primary completionEst.
Mar 31, 2025
CompletionEst.
Jul 31, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05933330
Responsible party
Sponsor
First posted
Jul 6, 2023
Start date
Apr 1, 2022
Primary completion
Mar 31, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Mar 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion